Splenomegaly in FOLFOX-naïve stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy

International Journal of Clinical Oncology

Volumn 16, Issue 3, 2011, Pages 257-263

  Miura, Kazuhiro ^a   Nakano, Hiroshi ^a   Sakurai, Joe ^a   Kobayashi, Shinjiro ^a   Koizumi, Satoshi ^a   Arai, Tatsuhiro ^a   Shimamura, Tsukasa ^a   Makizumi, Ryoji ^a   Yamada, Kyoji ^b   Miyajima, Nobuyoshi ^c   Otsubo, Takehito ^a   Koike, Junki ^d  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE HOSPITAL   (Japan)

^b Kawasaki City Tama Hospital   (Japan)

^c Toyoko Hospital   (Japan)

^d ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Aspartate aminotransferase to platelet ratio index; Chemotherapy associated hepatotoxicity; Chemotherapy Na ve patients; Splenic volume index; Splenomegaly

Indexed keywords

ASPARTATE AMINOTRANSFERASE; BEVACIZUMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; OXALIPLATIN;

ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER STAGING; COLORECTAL CANCER; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE CLASSIFICATION; FEMALE; HISTOPATHOLOGY; HUMAN; LIVER INJURY; LIVER RESECTION; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OUTCOME ASSESSMENT; PANCYTOPENIA; PREDICTION; PRIORITY JOURNAL; RECURRENT CANCER; SPLENOMEGALY; STOMATITIS; THROMBOCYTE COUNT; VOLUMETRY;

ADENOCARCINOMA; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASPARTATE AMINOTRANSFERASES; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DRUG-INDUCED LIVER INJURY; FEMALE; FLUOROURACIL; HUMANS; LEUCOVORIN; MALE; MIDDLE AGED; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PLATELET COUNT; RETROSPECTIVE STUDIES; SPLENOMEGALY;

EID: 80052781452     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-010-0176-0     Document Type: Article

References (30)

1. de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938-2947. (Pubitemid 30644117)
2. Aranda E, Valladares M, Martinez-Villacampa M et al (2009) Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study. Ann Oncol 20:251-257.
3. Kalofonos HP, Aravantinos G, Kosmidis P et al (2005) Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Ann Oncol 16:869-877. (Pubitemid 40903911)
4. Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539-1544. (Pubitemid 46733080)
5. Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335-2342. (Pubitemid 38702844)
6. Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007-1016. (Pubitemid 351392040)
7. Adam R, Delvart V, Pascal G et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240:644-657 (discussion 657-658).
8. Blazer DG 3rd, Kishi Y, Maru DM et al (2008) Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 26:5344-5351.
9. Fernandez FG, Ritter J, Goodwin JW et al (2005) Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200:845-853. (Pubitemid 40744790)
10. Rubbia-Brandt L, Audard V, Sartoretti P et al (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15:460-466. (Pubitemid 38444550)
11. Vauthey JN, Pawlik TM, Ribero D et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24:2065-2072. (Pubitemid 46622116)
12. Aloia T, Sebagh M, Plasse M et al (2006) Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24:4983-4990. (Pubitemid 46631400)
13. Nakano H, Oussoultzoglou E, Rosso E et al (2008) Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247:118-124.
14. Watanabe S, Hosomi N, Kitade Y et al (2000) Assessment of the presence and severity of esophagogastric varices by splenic index in patients with liver cirrhosis. J Comput Assist Tomogr 24:788-794. (Pubitemid 32204311)
15. Parise ER, Oliveira AC, Figueiredo-Mendes C et al (2006) Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver Int 26:1095-1099. (Pubitemid 44548838)
16. Lin CS, Chang CS, Yang SS et al (2008) Retrospective evaluation of serum markers APRI and AST/ALT for assessing liver fibrosis and cirrhosis in chronic hepatitis B and C patients with hepatocellular carcinoma. Intern Med 47:569-575.
17. Zorzi D, Laurent A, Pawlik TM et al (2007) Chemotherapyassociated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 94:274-286. (Pubitemid 46423843)
18. McCormack L, Petrowsky H, Jochum W et al (2007) Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case-control study. Ann Surg 245:923-930. (Pubitemid 46809294)
19. Wicherts D, de Haas R, Sebagh M et al (2009) Liver regenerative nodular hyperplasia consecutive to preoperative chemotherapy: impact on outcome of liver surgery for colorectal metastases. J Clin Oncol 27(15s):suppl (abstr 4097).
20. Chun YS, Laurent A, Maru D et al (2009) Management of chemotherapy- associated hepatotoxicity in colorectal liver metastases. Lancet Oncol 10:278-286.
21. Nakano H, Ossoutzoglou E, Rosso E et al (2008) Blue liver syndrome increases morbidity after right hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. In: HPB, 8th world congress of the IHPBA, vol 10, suppl (abstr 1).
22. Ward J, Guthrie JA, Sheridan MB et al (2008) Sinusoidal obstructive syndrome diagnosed with superparamagnetic iron oxide-enhanced magnetic resonance imaging in patients with chemotherapy-treated colorectal liver metastases. J Clin Oncol 26:4304-4310.
23. Oki E, Kakeji Y, Taketomi A et al (2008) Transient elastography for the prediction of oxaliplatin-associated liver injury in colon cancer patients: a preliminary analysis. J Gastrointest Cancer 39(1-4):82-85.
24. Angitapalli R, Litwin AM, Kumar PR et al (2009) Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II-III colorectal cancer. Oncology 76:363-368.
25. Overman MJ, Maru DM, Charnsangavej C et al (2010) Oxaliplatin- mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol 28:2549-2555.
26. Kesmodel SB, Ellis LM, Lin E et al (2008) Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 26:5254-5260.
27. Reddy SK, Morse MA, Hurwitz HI et al (2008) Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 206:96-106. (Pubitemid 350267242)
28. Klinger M, Eipeldauer S, Hacker S et al (2009) Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 35:515-520.
29. Van Buren G 2nd, Yang AD, Dallas NA et al (2008) Effect of molecular therapeutics on liver regeneration in a murine model. J Clin Oncol 26:1836-1842.
30. Aussilhou B, Dokmak S, Faivre S et al (2009) Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol 16:1553-1559.